Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexrazoxane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 3/20 | 0.93 |
| ▸ | TOP2B known ✓ | Q02880 | 3/20 | 0.93 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.93 |
| ▸ | LMNA | P02545 | 1/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexrazoxane SCHEMBL27918475 | 1.00 | TOP2A (0.93) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL18400 | 0.96 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Razoxane SCHEMBL3339694 | 0.96 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL1586271 | 0.96 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Razoxane SCHEMBL9089 | 0.96 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL18188 | 0.94 | TOP2A (0.96) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Razoxane SCHEMBL27174203 | 0.94 | TOP2A (0.96) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Razoxane SCHEMBL27748349 | 0.94 | TOP2A (0.96) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL28086609 | 0.91 | TOP2A (0.89) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL5488431 | 0.88 | TOP2A (0.83) | TOP2ATOP2BPTGS1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8231 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-20250232860-A1 | SMART DOSING FOR CANCER THERAPY | OPTIMDOSING LLC (US) | 2025-07-17 | — | — | US | claimed |
| US-12300370-B2 | Smart dosing for cancer therapy | OptimDosing, LLC (US) | 2025-05-13 | — | — | US | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| EP-1599467-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-11-30 | — | — | EP | claimed |
| WO-2005110994-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050137141-A1 | Prodrug composition | HILFINGER JOHN (US) | 2005-06-23 | — | — | US | claimed |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-25 | — | — | US | claimed |
| WO-2004078747-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | claimed |
| US-6693100-B1 | USING DEXRAZOXANE | CYATHUS EXQUIERE PHARMAFORSCHUNGS GMBH (AT) | 2004-02-17 | — | — | US | claimed |
| EP-1214073-A2 | USE OF DEXRAZOXANE FOR TREATING PSORIASIS | Cyathus Exquirere Pharmaforschungs GmbH (AT) | 2002-06-19 | — | — | EP | claimed |
| US-20010039952-A1 | ULTRASOUND ENHANCED CHEMOTHERAPY | WALTER A. HACKER, PH. D | 2001-11-15 | — | — | US | claimed |
| US-6308714-B1 | Ultrasound enhanced chemotherapy | CORAJE, INC. | 2001-10-30 | — | — | US | claimed |
| WO-2001019358-A2 | USE DEXRAZOXANE FOR TREATING PSORIASIS | CYATHUS EXQUIRERE PHARMAFORSCHUNGS GMBH (AT) | 2001-03-22 | — | — | WO | claimed |